Biomarker | Change in MRI activity score | Change in BASDAI | ||
Placebo | Infliximab | Placebo | Infliximab | |
Baseline | ||||
IL-6 | −0.158 | −0.205*** | 0.062 | −0.258*** |
VEGF | 0.067 | −0.074 | 0.140 | −0.079 |
CRP | −0.047 | −0.291*** | 0.169 | −0.322*** |
Percentage change from baseline to week 2 | ||||
IL-6 | 0.080 | 0.260*** | 0.066 | 0.297*** |
VEGF | 0.110 | 0.243*** | 0.105 | 0.260*** |
CRP | 0.006 | 0.296*** | −0.017 | 0.347*** |
Percentage change from baseline to week 24 | ||||
IL-6 | −0.086 | 0.215** | 0.178 | 0.340*** |
VEGF | −0.101 | 0.170* | 0.148 | 0.330*** |
CRP | −0.090 | 0.243*** | 0.147 | 0.414*** |
*p<0.05.
**p⩽0.01.
***p⩽0.001.
BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; CRP, C-reactive protein; IL-6, interleukin-6; MRI, magnetic resonance imaging, VEGF, vascular endothelial growth factor.